⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20554565 | 0.67 | — | — | |
| SCHEMBL20554564 | 0.65 | — | — | |
| SCHEMBL20394202 | 0.65 | MPO (0.32) | — | |
| SCHEMBL1701441 | 0.64 | — | — | |
| SCHEMBL7547068 | 0.61 | — | — | |
| SCHEMBL3019925 | 0.60 | PDPK1 (0.39) | — | |
| SCHEMBL4072814 | 0.58 | — | — | |
| SCHEMBL1027666 | 0.58 | — | — | |
| SCHEMBL17045302 | 0.56 | CYP11B1 (0.40) | — | |
| SCHEMBL1029563 | 0.56 | MEN1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115650974-B | N- [5- (pyrimidine-2-amino) -2, 4-disubstituted phenyl ] -cis-pentadiene amide derivative and application thereof | 天津大学 | 2024-06-18 | — | — | CN | claimed |
| US-20240182441-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-06 | — | — | US | claimed |
| WO-2024002938-A1 | COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-01-04 | — | — | WO | claimed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | claimed |
| EP-4157267-A1 | EGFR TKIS FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | Astrazeneca AB (SE) | 2023-04-05 | — | — | EP | claimed |
| EP-4153601-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | Vanderbilt University (US) | 2023-03-29 | — | — | EP | claimed |
| CN-115776889-A | EGFR TKI for treatment of non-small cell lung cancer | 阿斯利康(瑞典)有限公司 | 2023-03-10 | — | — | CN | claimed |
| CN-115650974-A | N- [5- (pyrimidine-2-amino) -2,4-disubstituted phenyl ] -cis-pentadiene amide derivative and application thereof | 天津大学 | 2023-01-31 | — | — | CN | claimed |
| CN-115667273-A | Competitive and non-competitive inhibitors of muscarinic acetylcholine receptor M5 | 范德堡大学 | 2023-01-31 | — | — | CN | claimed |
| US-11524951-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | ASTRAZENECA AB (SE) | 2022-12-13 | — | — | US | claimed |
| EP-3229798-A2 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | Beta Pharma, Inc. (US) | 2017-10-18 | — | — | EP | claimed |
| WO-2017007756-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | RODIN THERAPEUTICS, INC (US) | 2017-01-12 | — | — | WO | claimed |
| WO-2016094821-A2 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2016-06-16 | — | — | WO | claimed |
| EP-3009431-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | Astrazeneca AB (SE) | 2016-04-20 | — | — | EP | claimed |
| US-20150119379-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2015-04-30 | — | — | US | claimed |
| EP-2736895-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | Astrazeneca AB (SE) | 2014-06-04 | — | — | EP | claimed |
| WO-2013014448-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2013-01-31 | — | — | WO | claimed |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-04-23 | — | — | US | claimed |
| EP-1483265-B1 | PURINE DERIVATIVES AS KINASE INHIBITORS | LILLY CO ELI (US) | 2006-11-22 | — | — | EP | claimed |
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY | 2005-04-28 | — | — | US | claimed |